
    
      The previous phase II study showed that gemcitabine and cisplatin combination (GP) is an
      effective regimen in triple negative breast cancer (TNBC). The potential therapeutic effects
      of GP in advanced TNBC deserve further evaluation yet. Eligible patients are randomly
      assigned to receive either GP or GT regimen to verify the hypothesis.
    
  